Fox Chase Cancer Center News

Researchers Find Papillary Renal Cell Carcinoma Unresponsive to Sunitinib

CHICAGO, IL (June 2, 2010) – Of the more than 38,000 Americans diagnosed with renal cell carcinoma (RCC) each year, approximately 20 percent have non-clear cell forms of the disease. New findings shows that a non-clear cell form of kidney cancer known as papillary RCC, which accounts for 12 percent of all RCC, responds differently to sunitinib – a standard frontline treatment for RCC.  In a small but decisive Phase II trial, the researchers found that sunitinib was not effective in patients with this form of the disease. The terms clear- and non-clear cell refer to the general appearance of the cancer cells under a microscope.

VIEW STORY

Fox Chase Researchers to Present at American Urological Association

PHILADELPHIA (June 1, 2010) – Fox Chase Cancer Center researchers will present three abstracts at the 2010 annual meeting of the American Urological Association (AUA) that demonstrate progress in the use of the R.E.N.A.L. Nephrometry Scoring to characterize renal mass anatomy and allow standardization of surgical decision-making and comparison of outcomes in patients with kidney cancers.

VIEW STORY

New GIST Studies Look to Overcome TKI Resistance

Fox Chase Researchers Continue Commitment to Rare GIST Tumors

Several enrolling clinical trials are exploring avenues to overcoming TKI resistance.

The management of gastrointestinal stromal tumors (GIST) was revolutionized with the introduction of tyrosine kinase

VIEW STORY